Remove Clinical Research Remove Regulations Remove Therapies
article thumbnail

Can vertical AI advance cell and gene therapies? 

Drug Discovery World

Andrew Busey , Co-Founder, Form Bio discusses why vertical AI is set to reshape the cell and gene therapy sector. The cell and gene therapy industry is no exception to this digital transformation. It is imperative for the industry to communicate the precise composition and attributes of these therapies to regulatory bodies.

Therapies 162
article thumbnail

Incentivizing Participation: The Evolving Role of Patient Payments in Clinical Research

Vial

Clinical research is an integral component of the healthcare ecosystem. It is pivotal in the development of cutting-edge treatments, therapies, and interventions for a wide array of diseases. Patient Payments in Clinical Research: Perception Over the Years In the U.S.,

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

GxP Best Practices for Safer, Smarter, Faster Clinical Research

Advarra

In the clinical research space, GxP is a set of quality regulations and guidelines designed to establish the safety, efficacy, and integrity of pharmaceuticals, medical devices, and clinical trials. This blog explores key concepts, regulations, and the importance of GxP in delivering successful clinical trials.

article thumbnail

Distinguishing the Roles of Preclinical vs. Clinical CROs in Clinical Research

Vial

Distinguishing the Roles of Preclinical vs. Clinical CROs in Clinical Research Randomized clinical trials are the gold-standard of evidence-based medicine, representing the culmination of the long, arduous drug development pipeline.

article thumbnail

2024 predictions: Experts comment on AI, ML and automation

Drug Discovery World

In the upcoming year, we will see the expansion of new, more complex markets and updated requirements from regulators. Ensuring sufficient and timely patient enrollment in a rapidly growing number of cell and gene therapy clinical trials is becoming a bottleneck to advancing potentially life-saving therapies.

article thumbnail

Looking for Opportunities to Accelerate Clinical Research in Rare Diseases

LifeSciVC

It could also encourage more investment in the space and make us better partners to regulators and payors alike. We already have the first-ever clinical-stage NBD1 stabilizer and a second series of highly potent NBD1 stabilizers that are advancing to Phase 1 this summer.

article thumbnail

Thermo Fisher Scientific acquires real-world evidence provider

Drug Discovery World

Thermo Fisher Scientific has completed its acquisition of CorEvitas, a provider of real-world evidence for approved medical treatments and therapies, for $912.5 We are very excited to welcome our new CorEvitas colleagues to Thermo Fisher,” said Marc Casper, Chairman, President and Chief Executive Officer of Thermo Fisher.